{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-010321","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.906410+00:00","generated_at":"2026-05-31T15:19:41.578559+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuroBo licenses NB-01 to MThera Pharma for diabetic neuropathy; terms undisclosed","bullets":["Exclusive license grants MThera rights to develop and commercialize NB-01 for painful diabetic neuropathy.","MThera may conduct a Phase 3 trial in the U.S. and South Korea; NeuroBo to focus on DA-1726 and DA-1241.","Phase 2 efficacy data cited by MThera; financial terms not disclosed.","NeuroBo CEO says deal reflects commitment to out-license legacy assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-010321","json":"https://secwatch.observer/filing/0001558370-24-010321.json","markdown":"https://secwatch.observer/filing/0001558370-24-010321.md","text":"https://secwatch.observer/filing/0001558370-24-010321.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/0001558370-24-010321-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024010321/nrbo-20240730x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:19:41.578559+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}